Lilly is suing several US companies that are allegedly selling illegal versions of its weight loss candidate, retatrutide.
Recommended changes to the US immunisation schedule by President Trump have been met with widespread retaliation.
The latest round brings the total capital raised by Remepy to $62m.
The authorisation is based on data from the HARMONi-6 multi-centre Phase III study that was conducted in China.
Repligen’s $1.5bn purchase of BioLife Solutions adds CryoStor biopreservation to its bioprocessing portfolio, underscoring pharma’s shift toward integrated cell and gene therapy supply chains.
Infinimmune is targeting first-in-human studies with its longer-lasting monoclonal antibodies in 2027.
